No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SON Sonoco Products
- 50.880
- +1.270+2.56%
Close Jul 12 16:00 ET
- 51.160
- +0.280+0.55%
Post 18:52 ET
5.00BMarket Cap12.85P/E (TTM)
51.040High49.680Low836.96KVolume50.100Open49.610Pre Close42.44MTurnover0.86%Turnover Ratio10.60P/E (Static)98.26MShares61.73052wk High2.07P/B4.95BFloat Cap48.22052wk Low2.04Dividend TTM97.29MShs Float63.201Historical High4.01%Div YieldTTM2.74%Amplitude7.481Historical Low50.708Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
BofA Securities Adjusts Price Target on Sonoco Products to $61 From $64
Sonoco Products (SON) has an average outperform rating and price target range of $53 to $65, according to analysts polled by Capital IQ.Price: 49.91, Change: +0.97, Percent Change: +1.98
Express News | Sonoco Products Co : BofA Global Research Cuts Price Objective to $61 From $64
Sonoco Products Is Maintained at Buy by Citigroup
Sonoco Products Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Sonoco Prods, Lowers Price Target to $60
Sonoco Prods Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 23.71% Citigroup $64 → $60 Maintains Buy 05/03/2024 17.53% Wells Fargo $56 → $57 Maintains Equa
Express News | Sonoco Products Co : Citigroup Cuts Target Price to $60.00 From $64.00
Comments
Despite recent insider selling at Sonoco Products, shareholders need not worry deeply as insiders retain considerable company ownership, suggesting alignment with shareholders. Notably, the buying activity over the past year signals insider enthusiasm.
One Sonoco Products Insider Raised Stake By 99% In Previous YearSonoco's decent ROE comes with high debt levels, indicating risk. High ROEs without excessive debt denote good quality. Among companies with similar debt-to-equity ratios, a higher ROE is preferable.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Oak Street Health(OSH.US$ -up 26.6%
2. $Baidu(BIDU.US$ -up 7.5%
3. $BP PLC(BP.US$ -up 3.2%
4. $Fiserv(FISV.US$ -up 2.4%
5. $Mitsubishi UFJ Financial Group(MUFG.US$ -up 1.4%
6. $GlaxoSmithKline(GSK.US$ -up 0.8%
7. $Microsoft(MSFT.US$ -up 0.7%
8. $Sanofi(SNY.US$ -up 0.5%
9. $Activision Blizzard(ATVI.US$ -up 0.4% ...
Gap Ups
1. $Oak Street Health(OSH.US$ -up 26.6%
2. $Baidu(BIDU.US$ -up 7.5%
3. $BP PLC(BP.US$ -up 3.2%
4. $Fiserv(FISV.US$ -up 2.4%
5. $Mitsubishi UFJ Financial Group(MUFG.US$ -up 1.4%
6. $GlaxoSmithKline(GSK.US$ -up 0.8%
7. $Microsoft(MSFT.US$ -up 0.7%
8. $Sanofi(SNY.US$ -up 0.5%
9. $Activision Blizzard(ATVI.US$ -up 0.4% ...
+15
8
Gapping up
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
6
Upgrades
• $Coupang(CPNG.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
• $Coupang(CPNG.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
14
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg